Aptinyx Inc. (APTX): Price and Financial Metrics
APTX Stock Summary
- The ratio of debt to operating expenses for Aptinyx Inc is higher than it is for about just 0.3% of US stocks.
- With a price/sales ratio of 116.33, Aptinyx Inc has a higher such ratio than 96.73% of stocks in our set.
- As for revenue growth, note that APTX's revenue has grown -57.37% over the past 12 months; that beats the revenue growth of only 4.68% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Aptinyx Inc, a group of peers worth examining would be RESN, BCDA, HRTX, MRKR, and ACRS.
- Visit APTX's SEC page to see the company's official filings. To visit the company's web site, go to www.aptinyx.com.
APTX Stock Price Chart Interactive Chart >
APTX Price/Volume Stats
| Current price | $2.63 | 52-week high | $6.47 |
| Prev. close | $2.72 | 52-week low | $2.42 |
| Day low | $2.57 | Volume | 278,480 |
| Day high | $2.70 | Avg. volume | 538,218 |
| 50-day MA | $3.33 | Dividend yield | N/A |
| 200-day MA | $3.57 | Market Cap | 176.13M |
Aptinyx Inc. (APTX) Company Bio
Aptinyx Inc. develops therapeutics for neurological disorders. The company is focused on the development of drugs that interact with the NMDA receptor, and the company says it will use the funds to advance drugs for chronic pain, post-traumatic stress disorder (PTSD) and cognitive impairment in Parkinson’s disease. The company was founded in 2015 and is based in Evantson, Illinois.
Latest APTX News From Around the Web
Below are the latest news stories about Aptinyx Inc that investors may wish to consider to help them evaluate APTX as an investment opportunity.
Aptinyx shares gain after resuming mid-stage study of NYX-458 in cognitive impairmentAptinyx (APTX) has recommenced patient screening in a Phase 2 study of NYX-458 in patients with mild cognitive impairment and dementia associated with Parkinson’s disease and dementia with Lewy bodies, following temporary suspension due to escalation of the COVID-19.The company anticipates data in H2 2022. The study will evaluate daily oral dosing... |
Aptinyx Stock Is Trading Higher After Restarting NYX-458 Study In Dementia Associated Cognitive ImpairmentAptinyx Inc (NASDAQ: APTX) has restarted patient screening in a Phase 2 study evaluating NYX-458 in patients with mild … |
Aptinyx (NASDAQ:APTX) Shareholders Have Enjoyed A 32% Share Price GainAptinyx Inc. ( NASDAQ:APTX ) shareholders might be concerned after seeing the share price drop 22% in the last month... |
Aptinyx Inc. (APTX) CEO Norbert Riedel on Q4 2020 Results - Earnings Call TranscriptAptinyx Inc. (APTX) Q4 2020 Earnings Conference Call March 24, 2021 05:00 PM ET Company Participants Nick Smith - Vice President of Corporate Development & Investor Relations Norbert Riedel - Chief Executive Officer Ashish Khanna - Chief Financial Officer & Chief Business Officer Andy Kidd - President & Chief Operating... |
Aptinyx Inc. (APTX) Q4 2020 Earnings Call TranscriptAt this time, I would like to turn the call over to Nick Smith, vice president of corporate development and investor relations of Aptinyx. On today's call, Norbert Riedel, our chief executive officer, will discuss our business and clinical development progress, and Ashish Khanna, our chief financial officer, and the chief business officer will review our financial results. |
APTX Price Returns
| 1-mo | -16.51% |
| 3-mo | -37.38% |
| 6-mo | -17.30% |
| 1-year | -0.75% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -23.99% |
| 2020 | 1.17% |
| 2019 | -79.32% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Continue Researching APTX
Want to see what other sources are saying about Aptinyx Inc's financials and stock price? Try the links below:Aptinyx Inc (APTX) Stock Price | Nasdaq
Aptinyx Inc (APTX) Stock Quote, History and News - Yahoo Finance
Aptinyx Inc (APTX) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...